260
Views
3
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Treatment patterns and related clinical consequences in adults with asthma

, PharmD, PhDORCID Icon, , PharmD & , PhD
Pages 739-747 | Received 07 Dec 2017, Accepted 14 Jun 2018, Published online: 24 Aug 2018
 

Abstract

Objective: A stepwise therapeutic management is recommended for asthma patients by the Global Initiative for Asthma (GINA). Little is known about the recommendations applied in real world settings. This study aims to associate Treatment step with clinical events in patients with mild or severe asthma. Methods: A retrospective claims database analysis included adult patients with mild (GINA step 1) or severe asthma (GINA step 4). Maximum Treatment Step was measured within the first and second 90-day period after index date (the first date of asthma diagnosis during the inclusion period). Step-down was defined as a Treatment Step change from a higher to lower step, while Step-up was defined as a Treatment Step change from a lower to higher step. The primary outcome was a composite endpoint of asthma-related clinical events, measured at the third 90-day period. Results and Conclusions: A total of 6,354 mild-asthma patients and 5,695 severe-asthma patients were included. In mild-asthma, when compared with No Change in Treatment Step, Step-down was associated with a lower risk of future clinical events [adjusted odds ratio (OR) 0.80, 95% confidence interval (95% CI); 0.69–0.94], while Step-up was not associated with a change in clinical events [OR 0.98, 95% CI: 0.77–1.27]. In severe-asthma patients, Step-down was not associated with a change in clinical events [OR 0.94, 95% CI: 0.81–1.10], while Step-up was associated with a higher risk of future clinical events [OR 2.07, 95% CI: 1.29–3.33]. Our findings reassure the appropriateness of stepping-down treatment in mild-asthma patients. Clinicians should closely monitor and/or provide detailed asthma action plans for severe-asthma patients who are stepping-up treatment.

Declaration of Interest

All authors declare no conflict of interest related to this study.

Acknowledgements

We would like to acknowledge Samuel McGuffin from University of Colorado Denver, CO, USA for his help on language editing.

Additional information

Funding

This study is funded by the Department of Clinical Pharmacy Faculty Grant Program, University of Colorado.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.